SMILES,Name,Conditions,NCT_Number,Phases,Unapproval Probability,Approval Probability
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,_LEUPROLIDE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.0538418171541009,0.9461581828458988
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,_ESTRADIOL,SCHIZOPHRENIA|SCHIZOAFFECTIVE DISORDER|SCHIZOPHRENIFORM DISORDERS,NCT04093518,Phase 3,0.03569215407410308,0.9643078459258968
CC(=O)[O-],_ACETATE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.027082305773000505,0.9729176942269996
CC(=O)[O-],_ACETATE,DEPRESSION,NCT02837432,Early Phase 1,0.0993550323754194,0.9006449676245807
CC(=O)[O-],_ACETATE,BURN,NCT01413620,Phase 1,0.062449416038432536,0.9375505839615677
CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,_LEUPROLIDE_ACETATE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.07565993575765828,0.9243400642423418
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,_EXEMESTANE,OVARIAN CANCER,NCT04460807,Phase 3,0.14372312526986888,0.8562768747301311
C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,_FULVESTRANT,NEOPLASMS,NCT02530411,Phase 2,0.3512050106744144,0.6487949893255857
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,_LETROZOLE,OVARIAN CANCER,NCT03378297,Early Phase 1,0.09543002100802,0.90456997899198
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.14228098853521326,0.8577190114647868
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,SYSTEMIC LUPUS ERYTHEMATOSUS,NCT03492255,Not Applicable,0.001201641266119578,0.9987983587338805
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,_ABIRATERONE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.2393104154319053,0.7606895845680949
CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,_FLUTAMIDE,PCOS,NCT00930228,Phase 1,0.4323180331031528,0.5676819668968472
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,_DOCETAXEL,NEOPLASMS,NCT03693612,Phase 2,0.7802793252204494,0.21972067477955065
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,PROSTATE CANCER,NCT04194554,Phase 1|Phase 2,0.5041305970314675,0.4958694029685327
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,BREAST CANCER,NCT02826512,Phase 2,0.3148637004586334,0.6851362995413668
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,PANCREATIC CANCER,NCT03601923,Phase 2,0.5155193599075134,0.4844806400924866
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,OVARIAN NEOPLASMS,NCT03955471,Phase 2,0.5716231889820784,0.4283768110179215
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,_ENZALUTAMIDE,PROSTATIC NEOPLASMS,NCT03834519,Phase 3,0.3662714519320615,0.6337285480679384
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,_ENZALUTAMIDE,OVARIAN CANCER,NCT03464201,Phase 2,0.4087669969686395,0.5912330030313606
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,_ENZALUTAMIDE,BREAST CANCER,NCT02955394,Phase 2,0.40222141728914595,0.5977785827108538
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,OVARIAN CANCER,NCT03814447,Early Phase 1,0.8776757275455697,0.12232427245443027
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,NEOPLASMS,NCT03967223,Phase 2,0.8152601131659111,0.18473988683408887
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,SYSTEMIC LUPUS ERYTHEMATOSUS,NCT03492255,Not Applicable,0.5537849653131448,0.4462150346868553
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,PROSTATE CANCER,NCT03089203,Phase 1,0.9067051759270012,0.09329482407299898
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,PANCREATIC CANCER,NCT04390399,Phase 2,0.8471517394578808,0.15284826054211914
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,LIVER TRANSPLANT,NCT03577431,Phase 1|Phase 2,0.9936986779682156,0.0063013220317842825
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,BREAST CANCER,NCT02897700,Phase 1,0.2414173637492964,0.7585826362507037
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,OVARIAN CANCER,NCT03814447,Early Phase 1,0.8603802157625591,0.13961978423744095
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,NEOPLASMS,NCT03967223,Phase 2,0.7682169164476653,0.23178308355233465
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_EVEROLIMUS,LIVER TRANSPLANT,NCT03577431,Phase 1|Phase 2,0.524206702562147,0.475793297437853
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_EVEROLIMUS,END STAGE RENAL DISEASE,NCT03413722,,0.3731374237548146,0.6268625762451854
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,_GEMCITABINE,ADVANCED PANCREATIC CANCER,NCT04098081,Phase 2,0.467678168468677,0.5323218315313231
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,_PACLITAXEL,NEOPLASMS,NCT03693612,Phase 2,0.30442285803640196,0.695577141963598
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,_PACLITAXEL,PANCREATIC CANCER,NCT04054362,Phase 2,0.2152055159381029,0.784794484061897
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,PROSTATIC NEOPLASMS,NCT03834519,Phase 3,0.31043066381093265,0.6895693361890671
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,OVARIAN CANCER,NCT03378297,Early Phase 1,0.2349241285999675,0.7650758714000325
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,PROSTATE CANCER,NCT03810105,Phase 2,0.5015655010361568,0.498434498963843
NC(=O)CCC1NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(N)CSSCC(C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC1=O.NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,_VASOPRESSIN,HYPERTENSION,NCT04170751,Not Applicable,0.18960843381568127,0.8103915661843187
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,SYSTEMIC LUPUS ERYTHEMATOSUS,NCT03492255,Not Applicable,0.025693894673248584,0.9743061053267514
CCN(CC)CC(=O)Nc1c(C)cccc1C,_LIDOCAINE,PANCREATIC CANCER,NCT04048278,Early Phase 1,0.08483586862118678,0.9151641313788136
CCN(CC)CC(=O)Nc1c(C)cccc1C,_LIDOCAINE,"PAIN, CHRONIC",NCT02983682,Phase 3,0.31233845812362243,0.6876615418763776
CCN(CC)CC(=O)Nc1c(C)cccc1C,_LIDOCAINE,CONTRACEPTION,NCT02799641,Not Applicable,0.11147813557039936,0.8885218644296008
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,_VANCOMYCIN,ULCERATIVE COLITIS,NCT03759041,Phase 2,0.2508594535655908,0.7491405464344091
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,_AMIKACIN,"SHOCK, SEPTIC",NCT04178148,Not Applicable,0.1779879841524804,0.8220120158475198
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,_MYCOPHENOLATE_MOFETIL,SYSTEMIC LUPUS ERYTHEMATOSUS,NCT03492255,Not Applicable,0.05949286295344618,0.9405071370465541
S=P(N1CC1)(N1CC1)N1CC1,_THIOTEPA,BREAST CANCER,NCT01646034,Phase 3,0.3354603976678044,0.6645396023321954
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,ISCHEMIC HEART DISEASE,NCT03600961,,0.28891795156602484,0.7110820484339753
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,_LEUCOVORIN,PANCREATIC CANCER,NCT04390399,Phase 2,0.7968582405773477,0.2031417594226521
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,DEPRESSION,NCT02837432,Early Phase 1,0.07008560015724777,0.9299143998427524
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,PROSTATE CANCER,NCT00859781,Phase 2,0.12043547964477976,0.8795645203552201
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,SEPSIS,NCT04160676,Not Applicable,0.0012016412661195778,0.9987983587338805
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,"SHOCK, SEPTIC",NCT03592693,Phase 2,0.0012016412661195778,0.9987983587338805
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISOLONE,PROSTATIC NEOPLASMS,NCT04034095,,0.12372361503482887,0.8762763849651712
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_HYDROXYCHLOROQUINE,PROSTATE CANCER,NCT03513211,Phase 1|Phase 2,0.15437274988449404,0.8456272501155062
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_HYDROXYCHLOROQUINE,TYPE 1 DIABETES,NCT03428945,Phase 2,0.1565282489016027,0.8434717510983973
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,_OCTREOTIDE,GASTRO-ENTEROPANCREATIC NEUROENDOCRINE TUMOR,NCT03972488,Phase 3,0.19525769791028405,0.8047423020897159
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,DIABETIC FOOT,NCT03871049,Not Applicable,0.006358740229341978,0.993641259770658
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,CUSHING DISEASE,NCT03974789,,0.09404170761340104,0.9059582923865992
CC(C)NCC(O)COc1cccc2ccccc12,_PROPRANOLOL,OBSTRUCTIVE SLEEP APNEA,NCT03049306,Phase 2,0.3010888099727777,0.698911190027222
Clc1cccc(Cl)c1NC1=NCCN1,_CLONIDINE,CRITICAL ILLNESS,NCT03653832,Phase 3,0.17628579299565195,0.8237142070043482
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,OBSTRUCTIVE SLEEP APNEA,NCT02484300,Not Applicable,0.29870649401644106,0.7012935059835587
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,MIGRAINE DISORDERS,NCT03597529,Phase 2,0.1487095446676696,0.8512904553323304
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,_FOLIC_ACID,ANEMIA,NCT04404751,Not Applicable,0.06364529372304449,0.9363547062769556
C[N+](C)(C)CCO,_CHOLINE,GESTATIONAL DIABETES,NCT04302168,Not Applicable,0.21703628314299325,0.7829637168570066
NC(=O)CC[C@H](N)C(=O)O,_GLUTAMINE,BURN,NCT00985205,Phase 3,0.2895351443612062,0.7104648556387939
NC(=O)CC[C@H](N)C(=O)O,_L-GLUTAMINE,BURN,NCT00985205,Phase 3,0.2895351443612062,0.7104648556387939
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,_ASCORBIC_ACID,SEPSIS,NCT04160676,Not Applicable,0.18408393772358533,0.8159160622764148
Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1,_THIAMINE,SEPSIS,NCT04160676,Not Applicable,0.09552766103876607,0.904472338961234
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,_AZACITIDINE,PANCREATIC CANCER,NCT01845805,Phase 2,0.6837606842346241,0.3162393157653761
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,_SUNITINIB,BREAST CANCER,NCT02790580,Phase 2,0.20017188902276967,0.7998281109772303
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,_SUNITINIB,PANCREATIC NEUROENDOCRINE TUMORS,NCT02282059,,0.2471114970348499,0.7528885029651501
N[C@@H](Cc1ccc(O)cc1)C(=O)O,_TYROSINE,THYROID CANCER,NCT04521348,Phase 2,0.39301851518783215,0.6069814848121677
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,_DOXORUBICIN_HYDROCHLORIDE,OVARIAN CANCER,NCT04337632,Phase 3,0.3681961481086386,0.6318038518913616
O=C([O-])[O-].[Ca+2],_CALCIUM_CARBONATE,LIVER CIRRHOSIS,NCT02642874,Phase 3,0.04506585270530803,0.954934147294692
O=C([O-])[O-].[Ca+2],_CALCIUM_CARBONATE,OSTEOPOROSIS,NCT04550078,Not Applicable,0.12766400626509386,0.8723359937349062
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O,_CALCIFEDIOL,MYOCARDIAL INFARCTION,NCT02548364,Phase 3,0.015672274594366282,0.9843277254056336
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,SYSTEMIC LUPUS ERYTHEMATOSUS,NCT03953261,Phase 2,0.1359183236022406,0.8640816763977596
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,PROSTATE CANCER,NCT03769766,Phase 3,0.1785584307002024,0.8214415692997977
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,BREAST CANCER,NCT03980509,Phase 1,0.5826219353797738,0.4173780646202261
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,ULCERATIVE COLITIS,NCT02277223,Phase 3,0.044369505227008214,0.9556304947729916
CC(=O)N[C@@H](CS)C(=O)O,_ACETYLCYSTEINE,MILD COGNITIVE IMPAIRMENT,NCT03493178,Early Phase 1,0.18345544985584344,0.8165445501441565
Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,_VITAMIN_E,BREAST CANCER,NCT04463459,Not Applicable,0.0874702020564983,0.9125297979435016
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,_CHOLECALCIFEROL,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NCT04011930,Phase 2,0.012586748467034448,0.9874132515329656
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,_CHOLECALCIFEROL,END STAGE RENAL DISEASE,NCT04145492,Phase 2|Phase 3,0.003063359234907352,0.9969366407650928
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,_CHOLECALCIFEROL,ATOPIC DERMATITIS,NCT02537509,Phase 2,0.00992582892200151,0.9900741710779986
CN(C)C(=N)NC(=N)N,_METFORMIN,OVARIAN CANCER,NCT03378297,Early Phase 1,0.06245501631379417,0.9375449836862058
CN(C)C(=N)NC(=N)N,_METFORMIN,BREAST CANCER,NCT04559308,Phase 2,0.005,0.995
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,_PEMETREXED,NEOPLASMS,NCT02964013,Phase 1,0.508597238664968,0.4914027613350319
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,OVARIAN CANCER,NCT03378297,Early Phase 1,0.06717995237151539,0.9328200476284846
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,OVARIAN CANCER,NCT03378297,Early Phase 1,0.06717995237151539,0.9328200476284846
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,_MORPHINE,NEUROPATHIC PAIN,NCT01914042,Phase 2,0.36692027303076535,0.6330797269692345
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/CO)C(C)(C)CCC1,_VITAMIN_A,EFFICACY AND SAFETY,NCT03779776,Not Applicable,0.1899125410152192,0.8100874589847809
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,_PENTOXIFYLLINE,SCHIZOPHRENIA,NCT04094207,Phase 1|Phase 2,0.07046655493116426,0.9295334450688358
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,_ATORVASTATIN,BREAST CANCER,NCT02958852,Phase 2,0.05505716737002002,0.94494283262998
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,_ANGIOTENSIN,RHEUMATOID ARTHRITIS,NCT03770702,Phase 3,0.0481943393270039,0.951805660672996
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,_ANGIOTENSIN,OBESITY|HYPERTENSION,NCT03604289,Early Phase 1,0.1452529895698725,0.8547470104301276
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,_ANGIOTENSIN,OBESITY,NCT03777215,Early Phase 1,0.13108541134542667,0.8689145886545734
O=C(O)CCCC[C@@H]1CCSS1,_LIPOIC_ACID,"STROKE, ISCHEMIC",NCT04041167,Phase 3,0.08212038305258336,0.9178796169474168
O=c1[nH]cc(F)c(=O)[nH]1,_FLUOROURACIL,BREAST CANCER,NCT02897700,Phase 1,0.3326090579899802,0.6673909420100196
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,_IRINOTECAN,PANCREATIC CANCER,NCT04390399,Phase 2,0.7453829019949666,0.2546170980050335
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,RHEUMATOID ARTHRITIS,NCT03770923,Phase 3,0.19488542721145652,0.8051145727885433
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,OVARIAN HYPERSTIMULATION SYNDROME,NCT03794037,Phase 2,0.1963008831209113,0.8036991168790886
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,PAIN,NCT02793375,Phase 3,0.2673853823953791,0.7326146176046207
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,BREAST CANCER,NCT04172220,Not Applicable,0.11136973553635043,0.8886302644636495
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,_ROSUVASTATIN,OVARIAN CANCER,NCT03532139,Phase 2,0.24120559793359736,0.7587944020664027
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,_RAMIPRIL,MYOCARDIAL INFARCTION,NCT03715998,Phase 2,0.014620198627497047,0.9853798013725029
CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,_CANDESARTAN,MILD COGNITIVE IMPAIRMENT,NCT02646982,Phase 2,0.15709413117384347,0.8429058688261564
CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,_CANDESARTAN,PERIPHERAL NEUROPATHY,NCT03688633,Phase 2,0.06981988622590363,0.9301801137740964
CN1CCC[C@H]1c1cccnc1,_NICOTINE,MILD COGNITIVE IMPAIRMENT,NCT02720445,Phase 2,0.20117944918862016,0.79882055081138
COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1,_ESMOLOL,DIABETIC FOOT ULCER,NCT03998436,Phase 3,0.08692202192624464,0.9130779780737552
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,_DEXMEDETOMIDINE,BREAST CANCER,NCT03109990,Not Applicable,0.059978025842321425,0.9400219741576784
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,_DEXMEDETOMIDINE,CRITICAL ILLNESS,NCT03653832,Phase 3,0.03839775853917584,0.9616022414608244
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,_DEXMEDETOMIDINE,KIDNEY TRANSPLANTATION,NCT03327389,Not Applicable,0.03459864808698904,0.9654013519130109
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,_LOSARTAN,PANCREATIC CANCER,NCT03563248,Phase 2,0.08762411420344958,0.9123758857965504
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,_REGORAFENIB,THYROID CANCER,NCT02657551,Phase 2,0.9307523175883192,0.0692476824116805
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,_LENVATINIB,BREAST CANCER,NCT03168074,Phase 2,0.39071095056687616,0.6092890494331238
CN(C)C(=N)N=C(N)N.Cl,_METFORMIN_HYDROCHLORIDE,BREAST CANCER,NCT04170465,Phase 2,0.016580750328263026,0.9834192496717371
CN(C)C(=N)N=C(N)N.Cl,_METFORMIN_HYDROCHLORIDE,HEART FAILURE,NCT03331861,Phase 2,0.11240993083489956,0.8875900691651004
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,_DOXYCYCLINE,ULCERATIVE COLITIS,NCT02606032,Phase 2,0.1247794039614509,0.8752205960385492
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,_DOXYCYCLINE,INFERTILITY,NCT03824340,Not Applicable,0.12916676697148272,0.8708332330285176
CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,_TOPIRAMATE,SCHIZOPHRENIA,NCT02808533,Not Applicable,0.1648088213945106,0.8351911786054894
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,_DAPAGLIFLOZIN,PCOS,NCT04213677,Phase 3,0.05794933661772623,0.9420506633822741
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,_DAPAGLIFLOZIN,TYPE 1 DIABETES,NCT03899402,Phase 2|Phase 3,0.010299677325229356,0.9897003226747708
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,_DAPAGLIFLOZIN,NONALCOHOLIC STEATOHEPATITIS,NCT03723252,Phase 3,0.008392385713492745,0.9916076142865072
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,_DAPAGLIFLOZIN,AGING,NCT04401904,Phase 1|Phase 2,0.010299677325229356,0.9897003226747708
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,_DICLOFENAC,BREAST CANCER,NCT04511832,Not Applicable,0.17316917592496395,0.8268308240750362
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,_WARFARIN,PANCREATIC CANCER,NCT03536208,Early Phase 1,0.5059609719661863,0.4940390280338138
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,_SILDENAFIL,MAJOR DEPRESSIVE DISORDER,NCT04344678,Not Applicable,0.05964907833371238,0.9403509216662878
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,_SILDENAFIL_CITRATE,MAJOR DEPRESSIVE DISORDER,NCT04344678,Not Applicable,0.1728837737678317,0.8271162262321684
O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,_CILOSTAZOL,MAJOR DEPRESSIVE DISORDER,NCT04069819,Not Applicable,0.015790451916551904,0.984209548083448
CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@H](C(=O)N1CCC[C@H]1C(N)=O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O,_CALCITONIN,MIGRAINE DISORDERS,NCT04019496,,0.3613050992413957,0.6386949007586042
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,_MOXIFLOXACIN,SCHIZOPHRENIA,NCT04369391,Phase 1,0.5987715008260123,0.4012284991739877
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,_MOXIFLOXACIN,DIABETES,NCT01984827,Phase 1,0.441346164421176,0.5586538355788241
O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,_ROFLUMILAST,ASTHMA,NCT04108377,Phase 1,0.1686406213077732,0.8313593786922272
Cc1ncc([N+](=O)[O-])n1CCO,_METRONIDAZOLE,ULCERATIVE COLITIS,NCT02606032,Phase 2,0.11556620058668475,0.8844337994133152
Cc1ncc([N+](=O)[O-])n1CCO,_METRONIDAZOLE,INFECTION,NCT03844776,Not Applicable,0.1485384796893212,0.8514615203106791
Cc1ncc([N+](=O)[O-])n1CCO,_METRONIDAZOLE,PERIODONTITIS,NCT03733379,Phase 3,0.10461788286992887,0.8953821171300713
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,_RIVAROXABAN,LIVER CIRRHOSIS,NCT03005444,Not Applicable,0.18503897276763034,0.8149610272323696
CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,_FLUOXETINE,TYPE 1 DIABETES,NCT03228732,Early Phase 1,0.1960600042293224,0.8039399957706778
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,_DULOXETINE,ACUTE PAIN,NCT03549026,Not Applicable,0.03009039935066155,0.9699096006493384
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,_MINOCYCLINE,HYPERTENSION,NCT02133872,Phase 1,0.43852282168332174,0.5614771783166782
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,_MINOCYCLINE,"STROKE, ISCHEMIC",NCT03320018,Phase 2|Phase 3,0.2558206970785715,0.7441793029214285
CN(C/C=C/C#CC(C)(C)C)Cc1cccc2ccccc12,_TERBINAFINE,ULCERATIVE COLITIS,NCT02606032,Phase 2,0.15668969203723193,0.8433103079627681
N[C@@H]1CONC1=O,_CYCLOSERINE,MAJOR DEPRESSIVE DISORDER,NCT03511599,Phase 1,0.19684680203291471,0.8031531979670852
c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1,_PLERIXAFOR,"DIABETES MELLITUS, TYPE 1",NCT03182426,Phase 1|Phase 2,0.5770697595399504,0.4229302404600497
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,_CARVEDILOL,PROSTATE CANCER,NCT02944201,Phase 2,0.4819410739566861,0.5180589260433139
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,_CARVEDILOL,BREAST CANCER,NCT03879629,Phase 2,0.12949427378323386,0.8705057262167663
N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,_LIOTHYRONINE,HYPOTHYROIDISM,NCT03053115,Phase 2|Phase 3,0.13421266705235715,0.8657873329476429
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,_FENTANYL,PANCREATIC CANCER,NCT03434678,Phase 3,0.12613388523901709,0.8738661147609829
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,_FENTANYL,HEART FAILURE,NCT02421341,Not Applicable,0.12613388523901709,0.8738661147609829
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,_BUPIVACAINE,PANCREATIC CANCER,NCT03434678,Phase 3,0.10369166962176844,0.8963083303782317
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,_BUPIVACAINE,DIABETIC FOOT,NCT03871049,Not Applicable,0.044489403273992464,0.9555105967260076
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,_BUPIVACAINE,THYROID DISEASES,NCT04471597,Not Applicable,0.04476086246581493,0.9552391375341851
CC(C)c1cccc(C(C)C)c1O,_PROPOFOL,PANCREATIC CANCER,NCT03434678,Phase 3,0.1089561842309595,0.8910438157690405
CC(C)c1cccc(C(C)C)c1O,_PROPOFOL,CRITICAL ILLNESS,NCT03653832,Phase 3,0.03358185375793759,0.9664181462420623
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,_TRIAMCINOLONE,PROLIFERATIVE DIABETIC RETINOPATHY,NCT02447185,Phase 3,0.031723209648956294,0.9682767903510436
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,_TRIAMCINOLONE,PSORIASIS,NCT04117919,Phase 2,0.010765633485081895,0.989234366514918
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,_TRIAMCINOLONE_ACETONIDE,PROLIFERATIVE DIABETIC RETINOPATHY,NCT02447185,Phase 3,0.07090086334534043,0.92909913665466
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,_PIOGLITAZONE,OBESITY,NCT03866408,Early Phase 1,0.03248461221890283,0.967515387781097
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,_PIOGLITAZONE,GASTROPARESIS,NCT04300127,Early Phase 1,0.21933242231872466,0.7806675776812753
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,_NALBUPHINE,POSTOPERATIVE COMPLICATIONS,NCT03470077,Phase 2,0.1554869206775497,0.8445130793224503
CCN(CC)C(=O)C1(c2ccccc2)CC1CN,_MILNACIPRAN,DEPRESSION,NCT02783430,Phase 2|Phase 3,0.35135854177288106,0.6486414582271189
CCN(CC)C(=O)C1(c2ccccc2)CC1CN,_MILNACIPRAN,NEUROPATHIC PAIN,NCT01914042,Phase 2,0.35135854177288106,0.6486414582271189
C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,_NALOXONE,PAIN,NCT04034004,Early Phase 1,0.21501147916212374,0.7849885208378761
C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,_NALOXONE,"DIABETES MELLITUS, TYPE 1",NCT03149770,Phase 2,0.21501147916212374,0.7849885208378761
COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,_VANDETANIB,NEOPLASMS,NCT02530411,Phase 2,0.22972775691485695,0.7702722430851431
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Mg+2].[Mg+2].[Mg+2],_MAGNESIUM_CITRATE,DIABETIC NEPHROPATHY,NCT03824379,Phase 2,0.10833287931528578,0.8916671206847144
CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,_BROMOCRIPTINE,OBESITY,NCT03525002,Phase 2,0.22651130833746536,0.7734886916625348
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,_APATINIB,PANCREATIC CANCER,NCT04415385,Phase 2,0.11295308598205615,0.8870469140179438
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,_RIVOCERANIB,PANCREATIC CANCER,NCT04415385,Phase 2,0.11295308598205615,0.8870469140179438
CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O,_ALECTINIB,NEOPLASMS,NCT03194893,Phase 3,0.5900038686842852,0.4099961313157149
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,_TOPOTECAN,OVARIAN CANCER,NCT03763123,Phase 1,0.8841586068654529,0.1158413931345471
Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1,_TALAZOPARIB,BREAST CANCER,NCT04039230,Phase 1|Phase 2,0.90579908398278,0.0942009160172199
Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1,_TALAZOPARIB,PANCREATIC CANCER,NCT03637491,Phase 2,0.7219670537804613,0.27803294621953856
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,_EMPAGLIFLOZIN,END STAGE RENAL DISEASE,NCT03713190,Phase 2,0.00810360930515905,0.9918963906948408
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,_EMPAGLIFLOZIN,TYPE 1 DIABETES,NCT04201496,Phase 1,0.13392839848755633,0.8660716015124437
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,_EMPAGLIFLOZIN,GESTATIONAL DIABETES,NCT03215069,Phase 3,0.1075763481959023,0.8924236518040978
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,_EMPAGLIFLOZIN,PREDIABETIC STATE|INSULIN RESISTANCE,NCT04131582,Phase 3,0.0008955093482439279,0.999104490651756
CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1,_ERTUGLIFLOZIN,TYPE 2 DIABETES,NCT04029480,Phase 3,0.20800154344269106,0.7919984565573092
CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F,_EVOGLIPTIN,"DIABETES MELLITUS, TYPE 2",NCT04326166,,0.3585404232492461,0.641459576750754
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_ALBUTEROL,INSULIN RESISTANCE,NCT04558190,Not Applicable,0.20768329222854384,0.7923167077714562
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_SALBUTAMOL,INSULIN RESISTANCE,NCT04558190,Not Applicable,0.20768329222854384,0.7923167077714562
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,_CLOPIDOGREL,CRITICAL ILLNESS,NCT02285751,Phase 2,0.0031897370614553267,0.9968102629385448
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,_CLOPIDOGREL,DIABETES MELLITUS TYPE 2,NCT04305587,Phase 1,0.06464747782124329,0.9353525221787566
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,_LACTOSE,CRITICAL ILLNESS,NCT03464708,Phase 2,0.2147431325083918,0.7852568674916082
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,_MEGESTROL_ACETATE,BREAST CANCER,NCT03306472,Phase 2,0.07990164409208551,0.9200983559079146
NCCCC[C@H](N)C(=O)O,_LYSINE,HEART FAILURE,NCT03446651,Early Phase 1,0.4522451260561984,0.5477548739438016
CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,_DOBUTAMINE,MYOCARDIAL INFARCTION,NCT03289728,Not Applicable,0.15872570092190955,0.8412742990780905
CN1CCN2c3ncccc3Cc3ccccc3C2C1,_MIRTAZAPINE,BREAST CANCER,NCT02336750,Phase 3,0.1433152175259892,0.8566847824740109
NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,_FUROSEMIDE,NEPHROTIC SYNDROME,NCT03750136,Not Applicable,0.1304707447190394,0.8695292552809606
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,_CHLORHEXIDINE,BREAST CANCER,NCT02395614,Not Applicable,0.3672046200901408,0.6327953799098593
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,_CHLORHEXIDINE,INFECTION,NCT03844776,Not Applicable,0.08994473858122698,0.9100552614187734
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,_CHLORHEXIDINE,DIABETIC FOOT ULCER,NCT03503370,Phase 2,0.2510377198551612,0.7489622801448391
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,_CHLORHEXIDINE,PERI-IMPLANTITIS,NCT03977324,Not Applicable,0.04875805314595293,0.9512419468540472
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,_PARICALCITOL,PANCREATIC CANCER,NCT04054362,Phase 2,0.13733260653142482,0.8626673934685753
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,_ZOLPIDEM,PROSTATIC NEOPLASMS,NCT03436745,Phase 1,0.3628351938844661,0.6371648061155339
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,_MANNITOL,DIABETIC PERIPHERAL NEUROPATHY,NCT02728687,Phase 1|Phase 2,0.4822521588705041,0.5177478411294958
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2n1cnc2ccccc21,_GALETERONE,ADVANCED PANCREATIC CANCER,NCT04098081,Phase 2,0.3093980131445012,0.6906019868554987
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(/C(CO)=N/NC(=O)CCCCCN1C(=O)C=CC1=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,_ALDOXORUBICIN,PANCREATIC CANCER,NCT04390399,Phase 2,0.6864287871101474,0.31357121288985224
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,_RIFAXIMIN,TYPE 2 DIABETES,NCT03758144,Not Applicable,0.18847640018802536,0.8115235998119745
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,_RUCAPARIB,BREAST CANCER,NCT03911453,Early Phase 1,0.6520028762417569,0.34799712375824343
COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,_ZAFIRLUKAST,OVARIAN CANCER,NCT04339140,Phase 2,0.832883429912714,0.16711657008728598
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,_SUGAMMADEX,BURN,NCT03513406,Phase 3,0.33348494805251583,0.6665150519474841
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,_SUGAMMADEX,CRITICAL ILLNESS,NCT03791801,Not Applicable,0.2513106052087858,0.7486893947912143
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,_FLUTICASONE,PHARMACOKINETICS,NCT03739294,Phase 2,0.11844220838918212,0.8815577916108178
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],_FERUMOXYTOL,CORONARY ARTERY DISEASE,NCT02954510,Phase 3,0.5026538252284484,0.4973461747715516
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,_BARICITINIB,SYSTEMIC LUPUS ERYTHEMATOSUS,NCT03843125,Phase 3,0.4557174881376755,0.5442825118623243
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,_BARICITINIB,ATOPIC DERMATITIS,NCT03952559,Phase 3,0.446189600350196,0.5538103996498039
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,_TESTOSTERONE,PROSTATE CANCER,NCT03716739,Phase 2,0.020794279187853815,0.9792057208121464
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,_TESTOSTERONE,LIVER CIRRHOSIS,NCT03995251,Not Applicable,0.004633815551537071,0.9953661844484628
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1,_TESTOSTERONE_CYPIONATE,PROSTATE CANCER,NCT03716739,Phase 2,0.1534056853692717,0.8465943146307283
CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,_TESTOSTERONE_ENANTHATE,PROSTATE CANCER,NCT02090114,Phase 2,0.4398345738099919,0.5601654261900082
CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,_KETOCONAZOLE,PROSTATE CANCER,NCT00859781,Phase 2,0.5915236085781526,0.4084763914218476
O=C(O)c1cccnc1,_NIACIN,TYPE 2 DIABETES MELLITUS|OBESITY,NCT03867500,Early Phase 1,0.3192331665418755,0.6807668334581245
N[C@]1(C(=O)O)C[C@@H](F)C1,_FLUCICLOVINE,PROSTATE CANCER,NCT04009083,Not Applicable,0.2163603993812241,0.7836396006187759
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,_INDOCYANINE_GREEN,RHEUMATOID ARTHRITIS,NCT02680067,Phase 1,0.5444213494756043,0.4555786505243957
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,_TICAGRELOR,CRITICAL ILLNESS,NCT02285751,Phase 2,0.0215355191654402,0.9784644808345598
CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2,_PRASUGREL,CRITICAL ILLNESS,NCT02285751,Phase 2,0.05790108016245817,0.942098919837542
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,_MIFEPRISTONE,BREAST CANCER,NCT02788981,Phase 2,0.17760088499558566,0.8223991150044145
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,_MIFEPRISTONE,TYPE 2 DIABETES MELLITUS|INSULIN RESISTANCE,NCT03052400,Phase 2,0.19265424362651293,0.8073457563734873
COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,_DONEPEZIL,"DIABETES MELLITUS, TYPE 2",NCT04507438,Phase 2,0.15040472967961455,0.8495952703203856
CN1[C@H]2CCC[C@@H]1C[C@H](NC(=O)c1nn(C)c3ccccc13)C2,_GRANISETRON,SEPSIS,NCT03924518,Phase 2,0.10501592094478827,0.8949840790552119
CN(C)CCC=C1c2ccccc2COc2ccccc21,_DOXEPIN,BREAST CANCER,NCT02447211,Phase 2,0.3357749125633129,0.6642250874366872
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,_VILDAGLIPTIN,MAJOR DEPRESSIVE DISORDER,NCT04410341,Phase 1|Phase 2,0.006066687158205068,0.9939333128417951
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C,_SEMAGLUTIDE,TYPE 1 DIABETES,NCT03899402,Phase 2|Phase 3,0.07733673588484759,0.9226632641151524
O=C(Oc1ccccc1C(=O)O)c1ccccc1O,_SALSALATE,PCOS,NCT03229408,Phase 2,0.2335429575508015,0.7664570424491985
Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,_RESVERATROL,"DIABETES MELLITUS, TYPE 1",NCT03436992,Not Applicable,0.29684721277086945,0.7031527872291307
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,_BIA,PAIN,NCT04132609,Not Applicable,0.3592408016118957,0.6407591983881044
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,_BIA,MAJOR DEPRESSIVE DISORDER,NCT04137367,Not Applicable,0.08841702757796313,0.9115829724220368
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,_BIA,OBSTRUCTIVE SLEEP APNEA,NCT02666781,,0.5434240739611744,0.4565759260388257
CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O,_GLUCAGON,INSULIN SECRETION,NCT04347252,Phase 1,0.28181854176439003,0.71818145823561
CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,_SELICICLIB,CUSHING DISEASE,NCT03774446,Phase 2,0.6712091461804829,0.3287908538195172
O=[O+][O-],_OZONE,ISCHEMIC HEART DISEASE,NCT03660657,Phase 2|Phase 3,0.05985885362625092,0.9401411463737492
CC/C=C/CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)CC)C(C)C)C(C)O)C(C)CC,_TESAMORELIN,MILD COGNITIVE IMPAIRMENT,NCT02572323,Phase 2,0.20011288334775926,0.7998871166522408
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,_FLUTICASONE_FUROATE,PHARMACOKINETICS,NCT03739294,Phase 2,0.1880799942977204,0.8119200057022796
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,_CANAGLIFLOZIN,HEART FAILURE,NCT04252287,Phase 3,0.02870681954992162,0.9712931804500784
OC[C@H](O)[C@@H](O)[C@H](O)CO,_XYLITOL,END STAGE RENAL DISEASE,NCT04001036,Phase 2,0.3754949444123731,0.6245050555876267
C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(=O)O,_DOTATATE,NEUROENDOCRINE TUMORS,NCT04318561,Phase 1|Phase 2,0.1651019142940468,0.8348980857059531
Cc1cc2ncc(C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N)cn2n1,_ANAGLIPTIN,TYPE 2 DIABETES,NCT04267601,,0.4076072780979633,0.5923927219020367
CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC,_RACLOPRIDE,MAJOR DEPRESSIVE DISORDER,NCT03026036,,0.5972639154525706,0.4027360845474295
NC(=O)C1(NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](Cc2csc3ccccc23)NC(=O)C2CCNCC2)CCNCC1,_RELAMORELIN,GASTROPARESIS|DIABETES MELLITUS,NCT03420781,Phase 3,0.43301370419514257,0.5669862958048575
CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](C(N)=O)C(C)C,_SECRETIN,PANCREATIC CANCER,NCT03404661,,0.7273515381014329,0.2726484618985669
CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1,_CARIPRAZINE,MAJOR DEPRESSIVE DISORDER,NCT03739203,Phase 3,0.4694388763303457,0.5305611236696544
CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1,_CARIPRAZINE,SCHIZOPHRENIA,NCT03817502,Phase 3,0.4563013460174398,0.5436986539825602
CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1,_LASMIDITAN,MIGRAINE DISORDERS,NCT04396574,Phase 3,0.4249230645842563,0.5750769354157438
Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,_ALPELISIB,BREAST CANCER,NCT03056755,Phase 2,0.4624951580691224,0.5375048419308777
CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1,_DAROLUTAMIDE,PROSTATE CANCER,NCT04136353,Phase 3,0.28280125855665234,0.7171987414433478
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,_UPADACITINIB,ATOPIC DERMATITIS,NCT03569293,Phase 3,0.4329583111534148,0.5670416888465851
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,_UPADACITINIB,SYSTEMIC LUPUS ERYTHEMATOSUS,NCT04451772,Phase 2,0.4332203104878666,0.5667796895121332
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,_UPADACITINIB,ULCERATIVE COLITIS,NCT03006068,Phase 3,0.5139485273803256,0.4860514726196744
C[C@@H]1[C@H](c2ccccc2)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F,_UBROGEPANT,MIGRAINE DISORDERS,NCT04492020,Phase 3,0.4799694430668257,0.5200305569331742
